HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk
  • MJHLS Brand Logo

© 2022 MJH Life Sciences™ , NeurologyLive – Clinical Neurology News and Neurology Expert Insights. All rights reserved.

Consortium of MS Centers 2022: News Network

Key opinion leaders and presenters offer their insight on the latest advances in the management of patients with multiple sclerosis at the 2022 Consortium of Multiple Sclerosis Centers annual meeting.

EP. 1: State of Stem Cell Transplantation for Multiple Sclerosis

June 6th 2022

Jeffrey Cohen, MD, shared his perspective on the current use and study of stem cells for the treatment of multiple sclerosis, which he covered in the CMSC Presidential Lecture at the 2022 annual meeting.

EP. 2: Unanswered Questions About MS Stem Cell Transplantation

June 7th 2022

Jeffrey Cohen, MD, spoke about the topic of his CMSC Presidential Lecture at the 2022 annual meeting, stem cell transplantation in multiple sclerosis, and what questions remain unanswered in this realm of treatment.

EP. 3: What Is Known About COVID-19 Vaccine Response in MS

June 8th 2022

Daniel Kantor, MD, discussed his presentation at the 2022 CMSC annual meeting on COVID-19 vaccine response in patients with multiple sclerosis who are being treated with sphingosine 1 phosphate receptor modulators.

EP. 4: Remaining Questions Surrounding COVID-19 Vaccines in MS

June 9th 2022

Daniel Kantor, MD, discussed the data from his presentation at the 2022 CMSC annual meeting on COVID-19 vaccine response in patients with multiple sclerosis, and what questions are still lingering among the clinical community.

EP. 5: Hypothesis and Reasoning of the DISCO-MS Study

June 10th 2022

Robert Fox, MD, shared the details of the DISCO-MS study of disease-modifying therapy discontinuation in patients with multiple sclerosis, presented at the CMSC 2022 Annual Meeting.

EP. 6: The DISCO-MS Study Findings and Clinical Experience

June 11th 2022

Robert Fox, MD, offered perspective on data from the DISCO-MS study of disease-modifying therapy discontinuation in patients with multiple sclerosis and how it compares with day-to-day clinical practice.

EP. 7: Final Thoughts and Takeaways on MS DMT Discontinuation

June 12th 2022

Robert Fox, MD, who presented the DISCO-MS study results at the CMSC 2022 Annual Meeting, offered his closing thoughts on the data and the take-home messaging for clinicians.